Precision Thyroid Cancer Surgery With Molecular Fluorescent Guided Imaging (TARGET)
Detection of Thyroid Cancer and Central Lymph Node Metastases Using EMI-137 Enhanced Molecular Fluorescent Guided Imaging: a Multicentre Feasibility and
Sponsor: Erasmus Medical Center
This PHASE1 trial investigates Lymph Node Metastases and Papillary Thyroid Cancer and is currently completed. Erasmus Medical Center leads this study, which shows 9 recorded versions since 2018 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
May 2024 — Jul 2024 [monthly]
Completed PHASE1
-
Jan 2021 — May 2024 [monthly]
Completed PHASE1
-
Feb 2020 — Jan 2021 [monthly]
Completed PHASE1
Status: Recruiting → Completed
▶ Show 4 earlier versions
-
Dec 2019 — Feb 2020 [monthly]
Recruiting PHASE1
-
Jul 2018 — Dec 2019 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jun 2018 — Jul 2018 [monthly]
Not Yet Recruiting PHASE1
-
Apr 2018 — Jun 2018 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Erasmus Medical Center
- University Medical Center Groningen
For direct contact, visit the study record on ClinicalTrials.gov .